The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus
Strong, J. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3351 · Cited by 552
Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., & zur Hausen, H. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9470-9478.1998 · Cited by 353
LETCHWORTH, G. J., RODRIGUEZ, L. L., & DEL CBARRERA, J. (1999) · The Veterinary Journal · doi:10.1053/tvjl.1998.0303 · Cited by 253
Wong, L. H., Krauer, K. G., Hatzinisiriou, I., Estcourt, M. J., Hersey, P., Tam, N. D., Edmondson, S., Devenish, R. J., & Ralph, S. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28779 · Cited by 234
Cassady, K. A., Gross, M., & Roizman, B. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8620-8626.1998 · Cited by 189
Sun, W. H., Pabon, C., Alsayed, Y., Huang, P. P., Jandeska, S., Uddin, S., Platanias, L. C., & Rosen, S. T. (1998) · Blood · doi:10.1182/blood.v91.2.570 · Cited by 169
Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.
Lorence, R. M., Katubig, B. B., Reichard, K. W., Reyes, H. M., Phuangsab, A., Sassetti, M., Walter, R. J., & Peeples, M. E. (1994) · PubMed · Cited by 156
Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice
Huneycutt, B. S., Bi, Z., Aoki, C. J., et al. (1993) · Journal of Virology · doi:10.1128/jvi.67.11.6698-6706.1993 · Cited by 115
Coukos, G., Makrigiannakis, A., Kang, E. H., Caparelli, D., Benjamin, I., Kaiser, L. R., Rubin, S. C., Albelda, S. Μ., & Molnar-Kimber, K. L. (1999) · PubMed · Cited by 108
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Randall, R. E., & Goodbourn, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,571
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Self-citationThe Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
Kwon, J., & Bakhoum, S. F. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0761 · Cited by 1,293
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,296
Induction of an interferon response by RNAi vectors in mammalian cells
Bridge, A. J., Pebernard, S., Ducraux, A., Nicoulaz, A.-L., & Iggo, R. (2003) · Nature Genetics · doi:10.1038/ng1173 · Cited by 961
Weber, F., Wagner, V., Rasmussen, S. B., Hartmann, R., & Paludan, S. R. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.5059-5064.2006 · Cited by 954
Stojdl, D. F., Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 842
Self-citationHistory of Oncolytic Viruses: Genesis to Genetic Engineering
Kelly, E., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763
The interferon response circuit: Induction and suppression by pathogenic viruses
Haller, O., Kochs, G., & Weber, F. (2006) · Virology · doi:10.1016/j.virol.2005.09.024 · Cited by 681
De-novo and acquired resistance to immune checkpoint targeting
Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 662
Oncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Host defense, viruses and apoptosis
Barber, G. N. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400823 · Cited by 582
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Self-citationOptimizing oncolytic virotherapy in cancer treatment
Harrington, K., Freeman, D. J., Kelly, B., Harper, J., & Soria, J.-C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 513
Kirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Immune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Self-citationTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase
Kim, D.-H., Longo, M., Han, Y., Lundberg, P., Cantin, E., & Rossi, J. J. (2004) · Nature Biotechnology · doi:10.1038/nbt940 · Cited by 382
Thomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 367
Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301377 · Cited by 349
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Vesicular stomatitis virus: re-inventing the bullet
Lichty, B. D., Power, A. T., Stojdl, D. F., & Bell, J. C. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.03.003 · Cited by 319
Self-citationInduction of the interferon response by siRNA is cell type– and duplex length–dependent
Reynolds, A., Anderson, E. M., Vermeulen, A., Fedorov, Y., Robinson, K., Leake, D., Karpilow, J., Marshall, W. S., & Khvorova, A. (2006) · RNA · doi:10.1261/rna.2340906 · Cited by 317
Translational control of the innate immune response through IRF-7
Colina, R., Costa-Mattioli, M., Dowling, R. J. O., Jaramillo, M., Tai, L.-H., Breitbach, C. J., Martineau, Y., Larsson, O., Rong, L., Svitkin, Y. V., et al. (2008) · Nature · doi:10.1038/nature06730 · Cited by 316
Self-citationAntonio Chiocca, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc948 · Cited by 306
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
Self-citationKim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303
Oncolytic Viruses and the Immune System: The Dynamic Duo
Lemos de Matos, A., Franco, L. S., & McFadden, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.001 · Cited by 269
Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus
Diaz, R. M., Galivo, F., Kottke, T., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G., & Vile, R. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3974 · Cited by 264
Oncolytic herpes simplex virus vectors for cancer virotherapy
Varghese, S., & Rabkin, S. D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700537 · Cited by 264
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Gal-Ben-Ari, S., Barrera, I., Ehrlich, M., & Rosenblum, K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00480 · Cited by 254
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., Schuelke, M., Ayasoufi, K., Driscoll, C. B., Shim, K. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17011-z · Cited by 128
PKR in Innate Immunity, Cancer, and Viral Oncolysis
Balachandran, S., & Barber, G. N. (2007) · Cancer Genomics and Proteomics · doi:10.1007/978-1-59745-335-6_18 · Cited by 65
Metadata
- Authors
- Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C.
- Venue
- Nature Medicine
- Published
- 2000-07
- Volume
- 6
- Issue
- 7
- Pages
- 821-825
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1542691850
- Cited by
- 815
- References
- 14
- FWCI
- 13.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.